Chimeric Antigen Receptors (CARS) and Their Use in Medicine
AssigneeOslo Universitetssykehus Hf
InventorsElse Marit Inderberg, Sébastian Wälchli, Øyvind S. Bruland
Life of this patent
Estimating the term…
Loading patent…
AssigneeOslo Universitetssykehus Hf
InventorsElse Marit Inderberg, Sébastian Wälchli, Øyvind S. Bruland
Estimating the term…
Novel chimeric antigen receptors (CARs) are provided. When the CARs herein are expressed on the surface of immune cells, such immune cells may be directed to osteosarcoma cells as demonstrated with our in vivo data. In a murine intraperitoneal model, the tumor growth was significantly delayed for T cells expressing a CAR comprising a scFv from TP1 or TP3 antibodies. Immune cells expressing the CARs herein display therapeutic effect in the form of decreased tumor volume in a murine model simulating metastatic osteosarcoma. Combined with the finding that stem cells from healthy bone marrow were not significantly affected by T cells expressing any of the CARs, this disclosure provides an attractive cell therapeutic alternative for treatment of osteosarcoma.
A Chimeric Antigen Receptor (CAR) comprising an antigen binding domain, a hinge domain, a transmembrane domain and an intracellular signaling domain;
Dependencies are inferred from the claim text.